To review the literature on progress regarding (1) effectiveness of vaccines for prevention of otitis media (OM) and (2) development of vaccine antigens for OM bacterial and viral pathogens.
Data Sources
PubMed database of the National Library of Science.
Review Methods
We performed literature searches in PubMed for OM pathogens and candidate vaccine antigens, and we restricted the searches to articles in English that were published between July 2011 and June 2015. Panel members reviewed literature in their area of expertise.
Conclusions
Pneumococcal conjugate vaccines (PCVs) are somewhat effective for the prevention of pneumococcal OM, recurrent OM, OM visits, and tympanostomy tube insertions. Widespread use of PCVs has been associated with shifts in pneumococcal serotypes and bacterial pathogens associated with OM, diminishing PCV effectiveness against AOM. The 10-valent pneumococcal vaccine containing Haemophilus influenzae protein D (PHiD-CV) is effective for pneumococcal OM, but results from studies describing the potential impact on OM due to H influenzae have been inconsistent. Progress in vaccine development for H influenzae, Moraxella catarrhalis, and OM-associated respiratory viruses has been limited. Additional research is needed to extend vaccine protection to additional pneumococcal serotypes and other otopathogens. There are likely to be licensure challenges for protein-based vaccines, and data on correlates of protection for OM vaccine antigens are urgently needed.
Implications for Practice
OM continues to be a significant health care burden globally. Prevention is preferable to treatment, and vaccine development remains an important goal. As a polymicrobial disease, OM poses significant but not insurmountable challenges for vaccine development.
LieberthalASCarrollAEChonmaitreeT. The diagnosis and management of acute otitis media. Pediatr. 2013;131:e964-e99.
2.
ChonmaitreeTAlvarez-FernandezPJenningsK. Symptomatic and asymptomatic respiratory viral infections in the first year of life: association with acute otitis media development. Clin Infect Dis. 2015;60:1-9.
3.
PeltonSIPettigrewMMBarenkampSJ. Panel 6: Vaccines. Otolaryngol Head Neck Surg. 2013;148:E90-E101.
4.
BakaletzLO. Bacterial biofilms in the upper airway: evidence for role in pathology and implications for treatment of otitis media. Paediatr Respir Rev. 2012;13:154-159.
5.
Hall-StoodleyLHuFZGiesekeA. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA. 2006;296:202-211.
6.
RaynerMGZhangYGorryMC. Evidence of bacterial metabolic activity in culture-negative otitis media with effusion. JAMA. 1998;279:296-299.
7.
MillsNBestEJMurdochD. What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination. J Paediatr Child Health. 2015;51:300-306.
8.
BlockSLHedrickJHarrisonCJ. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829-833.
9.
CaseyJRPichicheroME. Changes in the frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
10.
CaseyJRAdlowitzDGPichicheroME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304.
11.
RevaiKMcCormickDPPatelJ. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatr. 2006;117:1823-1829.
12.
PumarolaFMaresJLosadaI. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol. 2013;77:1231-1236.
13.
HauILevyCCaeymaexL. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014;16:1-12.
14.
FletcherMAFritzellB. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int J Otolaryngol. 2012;2012:312935.
15.
Ben-ShimolSGivon-LaviNLeibovitzE. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Clin Infect Dis. 2014;59:1724-1732.
16.
TamirSORothYDalalI. Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era. Pediatr Infect Dis J. 2015;34:195-199.
17.
AbdelnourAArguedasADaganR. Etiology and antimicrobial susceptibility of middle ear fluid pathogens in Costa Rican children with otitis media before and after the introduction of the 7-valent pneumococcal conjugate vaccine in the National Immunization Program: acute otitis media microbiology in Costa Rican children. Medicine. 2015;94:e320.
18.
MaromTTanAWilkinsonGS. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr. 2014;168:68-75.
19.
SarasojaIJokinenJLahdenkariM. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J. 2013;32:517-520.
20.
GiannakopoulosPChrysovergisAXirogianniA. Microbiology of acute mastoiditis and complicated or refractory acute otitis media among hospitalized children in the postvaccination era. Pediatr Infect Dis J. 2014;33:111-113.
21.
HalgrimsonWRChanKHAbzugMJ. Incidence of acute mastoiditis in Colorado children in the pneumococcal conjugate vaccine era. Pediatr Infect Dis J. 2014;33:453-457.
22.
KordelukSOrgadRKrausM. Acute mastoiditis in children under 15 years of age in Southern Israel following the introduction of pneumococcal conjugate vaccines: a 4-year retrospective study (2009-2012). Int J Pediatr Otorhinolaryngol. 2014;78:1599-1604.
23.
KaplanSLCenterKJBarsonWJ. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. Clin Infect Dis. 2015;60:1339-1345.
24.
WiertsemaSPKirkhamLACorscaddenKJ. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule. Vaccine. 2011;29:5163-5170.
25.
Perez-TralleroEMarimonJMAlonsoM. Decline and rise of the antimicrobial susceptibility of Streptococcus pneumoniae isolated from middle ear fluid in children: influence of changes in circulating serotypes. Antimicrob Agents Chemother. 2012;56:3989-3991.
26.
GeneAdel AmoEInigoM. Pneumococcal serotypes causing acute otitis media among children in Barcelona (1992-2011): emergence of the multiresistant clone ST320 of serotype 19A. Pediatr Infect Dis J. 2013;32:e128-e133.
27.
KempfMVaronELepoutreA. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network. Clin Microbiol Infect. 2015;21:35-42.
28.
DaganRPattersonSJuergensC. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013;57:952-962.
29.
CorscaddenKJKirkhamLAThorntonRB. High pneumococcal serotype specific IgG, IgG1 and IgG2 levels in serum and the middle ear of children with recurrent acute otitis media receiving ventilation tubes. Vaccine. 2013;31:1393-1399.
30.
MenonVJCorscaddenKJFueryA. Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccination. Vaccine. 2012;30:3136-3144.
31.
PichicheroMECaseyJRAlmudevarA. Nonprotective responses to pediatric vaccines occur in children who are otitis prone. Pediatr Infect Dis J. 2013;32:1163-1168.
32.
EkstromNAhmanHPalmuA. Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy. Clin Vaccine Immunol. 2013;20:1034-1040.
33.
PloskerGL. 10-Valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine: a review in infants and children. Paediatr Drugs. 2014;16:425-444.
34.
TregnaghiMWSaez-LlorensXLopezP. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11:e1001657.
35.
LeachAJWiggerCAndrewsR. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules. BMC Pediatr. 2014;14:200.
36.
PrymulaRPeetersPChrobokV. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.see comment. Lancet. 2006;367:740-748.
37.
LagosREMunozAELevineMM. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin. 2011;7:511-522.
38.
IwataSKawamuraNKurokiH. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: a randomized, controlled study. Hum Vaccin Immunother. 2015;11:826-837.
39.
Ruiz-PalaciosGMGuerreroMLHernandez-DelgadoL. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011;7:1137-1145.
40.
KimCHKimJSChaSH. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 2011;30:e235-e243.
41.
LinTYLuCYChangLY. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan. J Formos Med Assoc. 2012;111:495-503.
42.
OmenacaFMerinoJMTejedorJC. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011;128:e290-e298.
43.
van den BerghMRSpijkermanJFrancoisN. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 2011;30:e170-e178.
44.
SilfverdalSASkerlikovaHZanovaM. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr Infect Dis J. 2011;30:e155-e163.
45.
OdusanyaOOKuyinuYAKehindeOA. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: booster dose and 2-dose catch-up regimens in the second year of life. Hum Vaccin Immunother. 2014;10:757-766.
46.
LalwaniSChatterjeeSChhatwalJ. Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India. Clin Vaccin Immunol. 2014;21:1292-1300.
47.
van den BerghMRSpijkermanJSwinnenKM. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56:e30-e39.
48.
HaynesLSzabaFMEatonSM. Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections. J Immunol. 2012;189:4921-4929.
49.
HeikkinenTBlockSLTobackSL. Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute otitis media in children. Pediatr Infect Dis J. 2013;32:669-674.
50.
Cuhaci CakirBBeyazovaUKemalogluYK. Effectiveness of pandemic influenza A/H1N1 vaccine for prevention of otitis media in children. Eur J Pediatr. 2012;171:1667-1671.
51.
NorhayatiMNHoJJAzmanMY. Influenza vaccines for preventing acute otitis media in infants and children. Cochrane Database Syst Rev. 2015;3:CD010089.
52.
MinaMJMcCullersJAKlugmanKP. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. mBio. 2014;5:e01040-13.
53.
MinaMJKlugmanKPRoschJW. Live attenuated influenza virus increases pneumococcal translocation and persistence within the middle ear. J Infect Dis. 2014;212:195-201.
54.
SeppäläEViskariHHoppuS. Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media. Vaccine. 2011;29:8615-8618.
55.
RodgersGLKlugmanKP. The future of pneumococcal disease prevention. Vaccine. 2011;29(suppl 3):C43-C48.
56.
XuJHDaiWJChenB. Using chitosan as a delivery system, ncreases protection against acute otitis media and invasive infection byStreptococcus pneumoniae. Scan J Immunol. 2015;81:177-185.
57.
PopeCOliverEHMaJ. Genetic conjugation of components in two pneumococcal fusion protein vaccines enhances paediatric mucosal immune responses. Vaccine. 2015;33:1711-1718.
CronLEStolKBurghoutP. Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun. 2011;79:3697-3710.
60.
FigueiraMMoschioniMDe AngelisG. Variation of pneumococcal pilus-1 expression results in vaccine escape during experimental otitis media (EOM). PLoS ONE. 2014;9:e83798.
61.
RoschJWIversonARHumannJ. A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media. EMBO Mol Med. 2014;6:141-154.
62.
XuXMengJWangY. Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1. J Microbiol. 2014;52:315-323.
63.
GoncalvesVMDiasWOCamposIB. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine. 2014;32:1113-1120.
PrymulaRPazdioraPTraskineM. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial. Vaccine. 2014;32:3025-3034.
66.
GlaxoSmithKline. Impact of GSK Biologicals’ 2189242A vaccine on nasopharyngeal carriage, safety and immunogenicity in children and infants. https://clinicaltrials.gov/ct2/show/NCT01262872. Accessed October 22, 2015.
BrooksWAChangLJShengX. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study. Vaccine. 2015;33:4610-4617.
RenDAlmudevarALPichicheroME. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children. Hum Vaccin Immunother. 2015;11:489-497.
71.
XuQCaseyJRPichicheroML. Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children. Mucosal Immunol. 2015;8:1110-1117.
72.
VerhaeghSJStolKde VogelCP. Comparative analysis of the humoral immune response to Moraxella catarrhalis and Streptococcus pneumoniae surface antigens in children suffering from recurrent acute otitis media and chronic otitis media with effusion. Clin Vaccine Immunol. 2012;19:914-918.
73.
SharmaSKCaseyJRPichicheroME. Reduced serum IgG responses to pneumococcal antigens in otitis-prone children may be due to poor memory B-cell generation. J Infect Dis. 2012;205:1225-1229.
74.
Van EldereJSlackMPLadhaniS. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14:1281-1292.
75.
MurphyTF. Vaccine for nontypeable Haemophilus influenzae: the future is now. Clin Vaccine Immunol. 2015;22:459-466.
76.
KodamaSAbeNHiranoT. A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa. Acta Oto-Laryngologica. 2011;131:989-996.
77.
KodamaSHiranoTNodaK. Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2011;29:1881-1890.
HanXWangCQiaoH. Mouse macrophage-derived chemokine as an adjuvant enhances the protective effect of P6 protein vaccine of nontypeableHaemophilus influenzae. Xibao Yu Fenzi Mianyixue Zazhi. 2014;30:913-916.
80.
WenXZhouFZhangY. Preparation and characterization of mouse monoclonal antibody against outer membrane protein P6 of Haemophilus influenzae. Xibao Yu Fenzi Mianyixue Zazhi. 2014;30:1051-1053.
81.
EubaBMoleresJViadasC. Relative contribution of P5 and Hap surface proteins to nontypable Haemophilus influenzae interplay with the host upper and lower airways. PLoS ONE. 2015;10:e0123154.
82.
LangereisJDde JongeMIWeiserJN. Binding of human factor H to outer membrane protein P5 of non-typeable Haemophilus influenzae contributes to complement resistance. Mol Microbiol. 2014;94:89-106.
83.
RoierSLeitnerDRIwashkiwJ. Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS ONE. 2012;7:e42664.
84.
NovotnyLAClementsJDBakaletzLO. Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization. Vaccine. 2013;31:3417-3426.
85.
SinghBAl-JubairTMorgelinM. The unique structure of Haemophilus influenzae protein E reveals multiple binding sites for host factors. Infect Immun. 2013;81:801-814.
86.
JalalvandFLittorinNSuYC. Impact of immunization with Protein F on pulmonary clearance of nontypeableHaemophilus influenzae. Vaccine. 2014;32:2261-2264.
87.
KaurRCaseyJRPichicheroME. Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children. Vaccine. 2011;29:1023-1028.
88.
KunthalertDNovotnyLAMassaHM. Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26. Hum Vaccin Immunother. 2013;9:625-635.
89.
WinterLEBarenkampSJ. Antibodies to the HMW1/HMW2 and Hia adhesins of nontypeable Haemophilus influenzae mediate broad-based opsonophagocytic killing of homologous and heterologous strains. Clin Vaccine Immunol. 2014;21:613-621.
90.
DavisGSPatelMHammondJ. Prevalence, distribution, and sequence diversity of hmwA among commensal and otitis media non-typeableHaemophilus influenzae. Infect Genet Evol. 2014;28:223-232.
91.
SuYCSinghBRiesbeckK. Moraxella catarrhalis: from interactions with the host immune system to vaccine development. Future Microbiol. 2012;7:1073-1100.
92.
OtsukaTKirkhamCJohnsonA. Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen ofMoraxella catarrhalis. Infect Immun. 2014;82:3503-3512.
93.
SmidtMBattigPVerhaeghSJ. Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model. PLoS ONE. 2013;8:e64422.
94.
ShafferTLBalderRBuskirkSW. Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2. PLoS ONE. 2013;8:e67881.
95.
JonesMMJohnsonAKoszelak-RosenblumM. Role of the oligopeptide permease ABC transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract. Infect Immun. 2014;82:4758-4766.
96.
GaoSRenDPengD. Late acyltransferase genes lpxX and lpxL jointly contribute to the biological activities ofMoraxella catarrhalis. J Med Microbiol. 2013;62:807-812.
97.
RenDYuSGaoS. Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis. Vaccine. 2011;29:4210-4217.
98.
HoopmanTCLiuWJoslinSN. Use of the chinchilla model for nasopharyngeal colonization to study gene expression by Moraxella catarrhalis. Infect Immun. 2012;80:982-995.
NovotnyLAClementsJDBakaletzLO. Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol. 2011;4:456-467.
101.
NovotnyLAJurcisekJAWardMOJr. Antibodies against the majority subunit of type IV pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media. Mol Microbiol. 2015;96:276-292.
102.
van SantenKLBednarczykRAAdjaye-GbewonyoD. Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. Pediatr Infect Dis J. 2013;32:1180-1184.
103.
DalyKAScott GiebinkGLindgrenBR. Maternal immunization with pneumococcal 9-valent conjugate vaccine and early infant otitis media. Vaccine. 2014;32:6948-6955.
104.
HolderRCKirseDJEvansAK. One third of middle ear effusions from children undergoing tympanostomy tube placement had multiple bacterial pathogens. BMC Pediatrics. 2012;12:87.
105.
MayanskiyNAlyabievaNPonomarenkoO. Bacterial etiology of acute otitis media and characterization of pneumococcal serotypes and genotypes among children in Moscow, Russia. Pediatr Infect Dis J. 2015;34:255-260.
106.
KaurRCzupKCaseyJR. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014;14:640.
107.
KhanMNSharmaSKFilkinsLM. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect. 2012;14:1102-1110.
108.
RonanderEBrantMJansonH. Identification of a novel Haemophilus influenzae protein important for adhesion to epithelial cells. Microbes Infect. 2008;10:87-96.
109.
JalalvandFSuYCMorgelinM. Haemophilus influenzae protein F mediates binding to laminin and human pulmonary epithelial cells. J Infect Dis. 2013;207:803-813.
110.
SuYCJalalvandFMorgelinM. Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity. Mol Microbiol. 2013;87:1245-1266.
111.
VerhaeghSJde VogelCPRiesbeckK. Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants. Vaccine. 2011;29:5603-5610.
112.
SuYCHallstromBMBernhardS. Impact of sequence diversity in the Moraxella catarrhalis UspA2/UspA2H head domain on vitronectin binding and antigenic variation. Microbes Infect. 2013;15:375-387.
113.
HallstromTNordstromTTanTT. Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding. J Immunol. 2011;186:3120-3129.
114.
EastonDMCrippsAWFoxwellAR. Mucosal immunization with the Moraxella catarrhalis porin m35 induces enhanced bacterial clearance from the lung: a possible role for opsonophagocytosis. Frontiers Immunol. 2011;2:13.
115.
BernhardSFleuryCSuYC. Outer membrane protein OlpA contributes to Moraxella catarrhalis serum resistance via interaction with factor H and the alternative pathway. J Infect Dis. 2014;210:1306-1310.
116.
Luke-MarshallNRSauberanSLCampagnariAA. Comparative analyses of the Moraxella catarrhalis type-IV pilus structural subunit PilA. Gene. 2011;477:19-23.
117.
CoxADSt MichaelFCairnsCM. Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera. Glycoconj J. 2011;28:165-182.
118.
HassanFRenDZhangW. Moraxella catarrhalis activates murine macrophages through multiple toll like receptors and has reduced clearance in lungs from TLR4 mutant mice. PLoS ONE. 2012;7:e37610.
